Back

The role of NT ProBNP and Galectin 3 in the follow up of patients with primary mitral regurgitation

31 August 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (3) - Treatment and outcome of mitral valve regurgitation Mitral Valve Regurgitation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Catalina Ileana Riebel

University of Medicine and Pharmacy of Cluj Napoca, Cluj Napoca (Romania)

7 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor D. Felbel (Ulm, DE)
Abstract Video
Presentation thumbnail
Doctor A. Vecerova (Prague, CZ)
Abstract Video
Presentation thumbnail
Doctor S. Elimeleh (Ramat Gan, IL)
Abstract Video
Presentation thumbnail
Doctor T. Avram (Cluj Napoca, RO)
Abstract Video

Access the full session

Session thumbnail
New perspectives in cardiology (3) - Treatment and outcome of mitral valve regurgitation

The Event

Event poster

ESC Congress 2025

31 August 2025 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Galectin 3 : possible tool for early detection of LV diastolic dysfunction in asymptomatic survivors of childhood, adolescent and young adult cancer
thumbnail
Congress Presentation
Echocardiographic predictors of left ventricular interstitial fibrosis in chronic primary mitral regurgitation with preserved ejection fraction: the underrecognized role of diastolic dysfunction
thumbnail
Congress Presentation
Beyond NT-proBNP: novel biomarkers enhance short- and intermediate-term risk prediction in tricuspid valve interventions

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources